Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Lynx1 Capital Management LP is named as a reporting person in SEC Form 4 filings. OQRO lists 24 transactions filed with the SEC under this name, the latest on Oct 26, 2026, each linked to the official Form 4.
Disclosures on record
24
Companies involved
4
10 buys, median −20.8 pts vs S&P 500, beat it 3 of 10 times.
Average −19.7 pts vs S&P 500. Each buy is one disclosure of open-market purchases in one company on one filing date, filed Nov 19, 2024 to Jun 30, 2026, measured from the first close after the filing. Past results, not a forecast.
Korro BioKRRO
4 disclosures · Oct 2026 · 4 bought
Oct 22, 2026Bought~$441Kdisclosed Oct 26
DetailsOfficial recordOct 26, 2026Bought~$295K
DetailsOct 22, 2026Bought~$118Kdisclosed Oct 26
DetailsOfficial recordOct 23, 2026Bought~$30Kdisclosed Oct 26
DetailsOfficial recordPassage BioPASG
11 disclosures · Nov 2024 – Jun 2026 · 11 bought
Jun 25, 2026Bought~$206Kdisclosed Jun 30
DetailsOfficial recordSep 12, 2025Bought~$138Kdisclosed Sep 16
DetailsOfficial recordSep 15, 2025Bought~$83Kdisclosed Sep 16
DetailsOfficial recordSep 11, 2025Bought~$2.3Kdisclosed Sep 16
DetailsOfficial recordJul 24, 2025Bought~$379K
DetailsOfficial recordJul 23, 2025Bought~$283Kdisclosed Jul 24
DetailsOfficial recordJul 22, 2025Bought~$71Kdisclosed Jul 24
DetailsOfficial recordDec 27, 2024Bought~$241Kdisclosed Dec 31
DetailsOfficial recordNov 25, 2024Bought~$147Kdisclosed Nov 27
DetailsOfficial recordNov 26, 2024Bought~$118Kdisclosed Nov 27
DetailsOfficial recordNov 27, 2024Bought~$20K
DetailsOfficial recordTscan TherapeuticsTCRX
8 disclosures · Nov 2024 – Dec 2025 · 8 bought
Dec 19, 2025Bought~$72Kdisclosed Dec 23
DetailsOfficial recordDec 22, 2025Bought~$68Kdisclosed Dec 23
DetailsOfficial recordDec 23, 2025Bought~$5.6K
DetailsOfficial recordMay 19, 2025Bought~$1.67Mdisclosed May 21
DetailsOfficial recordMay 20, 2025Bought~$1.44Mdisclosed May 21
DetailsOfficial recordDec 13, 2024Bought~$290Kdisclosed Dec 16
DetailsOfficial recordDec 12, 2024Bought~$96Kdisclosed Dec 16
DetailsOfficial recordNov 15, 2024Bought~$4.1Kdisclosed Nov 19
DetailsOfficial recordOct 21, 2025Bought~$3.28Mdisclosed Oct 24
DetailsOfficial recordAs of the latest filing on , Lynx1 Capital Management LP reported holding 1,624,789 shares of Korro Bio (KRRO), worth about $22.1M at the last close of $14 (Nov 13, 2026), held through a see footnote. Holdings are also on file at Passage Bio (PASG), Neuphoria Therapeutics (NEUP), Tscan Therapeutics (TCRX); together they are worth about $28.5M. In the last 12 months, Lynx1 Capital Management LP bought $1.24M in 8 open-market purchases.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Korro Bio KRRO | 1,624,789 | 1.62M see footnote | $14 | $22.1M | Oct 26, 2026 |
| Passage Bio PASG | 673,759 | 674K see footnote | $4 | $2.86M | Jun 25, 2026 |
| Neuphoria Therapeutics NEUP | 875,328 | 875K see footnote | $3 | $2.23M | Oct 21, 2025 |
| Tscan Therapeutics TCRX | 8,019,148 | 8.02M see footnote | $0 | $1.29M | Dec 23, 2025 |
Is this Lynx1 Capital Management LP’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Lynx1 Capital Management LP bought shares on the open market in 2024, 2025 and 2026 across 4 companies. Sales in 1 of the 4 years since 2023.
Lynx1 Capital Management LP reported 24 open-market purchases and 3 sales since 2023; purchases in 3 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $1.09M5×5 trades | — |
| 2025 | $7.49M12×12 trades | — |
| 2024 | $915K7×7 trades | — |
| 2023 | — | $64K3×3 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Oct 26, 2026, Lynx1 Capital Management LP reported holding 1,624,789 shares of Korro Bio (KRRO), held indirectly. At the last close of $14 on Nov 13, 2026, that is about $22.1M. This is the stake disclosed in filings, not a net worth.
In SEC filings of the last 12 months, Lynx1 Capital Management LP reported 8 open-market purchases worth $1.24M, and no open-market sale. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
Lynx1 Capital Management LP bought shares on the open market in 2024, 2025 and 2026 across 4 companies. Sales in 1 of the 4 years since 2023.
In SEC filings since 2023: the latest open-market purchase is from 2026; the latest open-market sale is from 2023.
4 companies: Passage Bio (PASG, 2024–2026), Korro Bio (KRRO, 2026), Tscan Therapeutics (TCRX, 2023–2025), Neuphoria Therapeutics (NEUP, 2025).
Lynx1 Capital Management LP reported 11 open-market purchases and 0 sales here, 2024 to 2026.
Lynx1 Capital Management LP reported 8 open-market purchases and 3 sales here, 2023 to 2025.
Lynx1 Capital Management LP reported 4 open-market purchases and 0 sales here, 2026.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
